Dogwood Therapeutics, Inc. · NASDAQ:DWTX
Dogwood Therapeutics — Corporate Update (October 2025)
32 slides from Dogwood Therapeutics's corporate update, Oct 9, 2025
Slide 1: Q4 2025 Update
NASDAQ: DWTX Q4 2025 Update Deep Commitment to Advancing First-in-Class New Therapeutic Treatments for Cancer Patients Suffering from Neuropathy
Slide 2: Forward-Looking Statements and Disclaimers
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 2 Forward-Looking Statements and Disclaimers Forward-Looking Statements Statements in this presentation contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to su
Slide 3: Executive Team with Extensive Drug Development and Commercialization Experience
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 3 Dogwood is Led by an Executive Team with Extensive Drug Development and Commercialization Experience DWTX Executive Team Greg Duncan Chairman & CEO R. Michael Gendreau MD, PhD CMO Ralph Grosswald SVP of Operations Angela Walsh CFO Management’s
Slide 4: Deep Commitment to Cancer Patients Suffering from Neuropathy
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 4 Deep Commitment to Cancer Patients Suffering from Neuropathy, with the Goal to Expand to Reducing General Cancer Pain and Acute Surgical Pain DWTX Research Pipeline
Slide 5: DWTX Ownership on a Fully Diluted Basis
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 5 DWTX Ownership on a Fully Diluted Basis, Presuming Positive Shareholder Vote • Upon conversion of the existing Preferred Stock into common stock following shareholder approval, there will be ~ 30 million shares of common stock on a fully dilut
Slide 6: Halneuron Research Program Overview
CONFIDENTIAL – Dogwood Therapeutics, Inc. Halneuron® Research Program Overview
Slide 7: Halneuron - Logical Approach Fulfilling Requirements of an Ideal Analgesic
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 7 Halneuron® - Logical Approach that We Believe Fulfills Many Requirements Of An Ideal Analgesic Halneuron® Therapeutic Profile Demonstrated in Clinical Research to-date Halneuron’s® Nav 1.7 Inhibition Mechanism Supported by Real World Patient E
Slide 8: CINP Represents a Major Unmet Medical Need
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 8 CINP Represents a Major Unmet Medical Need • Approximately 20M new patients were diagnosed with cancer worldwide in 2022 ⎼ ~2M new cancer cases in the US in 2025 ⎼ ~40% of cancer patients live with chronic pain • Over 50% of cancer patients ar
Slide 9: Vicious Cycle With Opioid Pain Therapies
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 9 Vicious Cycle With Opioid Pain Therapies Taking Opioids to Manage Pain Experience Euphoria; Build Up of Tolerance Severe Side Effects, Withdrawal; Addictive “High” Increase Dosage: Manage Pain and Worsen Withdrawal Symptoms Large Scale Addicti
Slide 10: Ability to Effectively Treat CINP Opens a Large Market Opportunity
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 10 Ability to Effectively Treat CINP Opens a Large Market Opportunity • Medications like duloxetine, gabapentin, pregabalin, or tricyclic antidepressants and opioids are used to help manage neuropathic pain ⎼ Opioids account for 38%-58% of CINP
Slide 11: Our Approach - What is Halneuron?
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 11 Our Approach - What is Halneuron®? • Halneuron® is Tetrodotoxin (TTX), a sodium channel blocker and potent small molecule found in puffer fish and several other marine animals (not a peptide or protein) • Halneuron® is administered as a sub-Q
Slide 12: Sodium Channels in Mammals
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. Sodium Channels in Mammals • There are 9 primary sodium channels known in mammals • The 1.7, 1.8 and 1.9 channels are directly related to pain transmission in the peripheral nervous system • Halneuron is specific for the 1.7 channel 12
Slide 13: Halneuron is Selective for the Nav 1.7 Channel in Peripheral Tissues
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 13 Halneuron® is Selective for the Nav 1.7 Channel in Peripheral Tissues • Nav 1.7 through 1.9 are found in the peripheral nervous system (PNS) and are involved in regulating pain signaling • Halneuron® has low affinity for cardiac sodium channe
Slide 14: Preclinical Efficacy of Halneuron in Rat Oxaliplatin-Induced Neuropathic Pain Study
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 14 Preclinical Efficacy of Halneuron® in Rat Oxaliplatin-Induced Neuropathic Pain Study • Adult male Sprague-Dawley rats. • Oxaliplatin 4 mg/kg, injected intravenously, twice a week, repeated up to 9 times to induce mechanical allodynia. • Paw w
Slide 15: Halneuron Pain Reduction in Preclinical Paw Withdrawal Model Compared to VX548
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 15 Halneuron® Pain Reduction in Preclinical Paw Withdrawal Model Compared to VX548 (TTX 1000 X lower dose) Halneuron® Efficacy Builds as Evidenced by Higher Pre-Dose Threshold Prior to Future Doses Halneuron® Efficacy Compares Favorably with Rec
Slide 16: Previous Phase 2 Human Study - Cancer Related Pain
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 16 Previous Phase 2 Human Studies- Cancer Related Pain (CRP) Cancer Related Pain Phase 2 Study (n=165) • Tested for efficacy and safety of Halneuron® for moderate to severe inadequately controlled pain post cancer therapy ⎼ Included neuropathic
Slide 17: Phase 2 CRP Study - Statistically Significant Pain Reduction
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 17 Phase 2 CRP Study - Halneuron® Demonstrated Statistically Significant Pain Reduction 51% of patients on Halneuron® experienced a ≥30% reduction in pain vs. 35% on Placebo TTX 1 Placebo 2 Difference Responder 3 33 51% 29 35% 16% Non-Responder
Slide 18: Phase 2 CRP Study: Long Duration of Pain Relief for Initial Responders
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 18 Phase 2 CRP Study: Long Duration of Pain Relief for Initial Responders Responders to Halneuron® Responders to Placebo Placebo response was temporary 0 10 20 30 40 50 60 70 80 90 100 150 200 250 300 350 400 450 500 550 Days • A “Responder” is
Slide 19: Previous Phase 2a Signal-Seeking Study to Treat CINP
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 19 Previous Phase 2a Signal-Seeking Study to Treat CINP CINP Phase 2a Signal-Seeking Study (n=125) • Randomized, double-blind, dose-finding, placebo-controlled, multicenter study evaluating efficacy and safety of Halneuron® in CINP patients ⎼ Te
Slide 20: Halneuron CINP Adverse Event Profile
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 20 Halneuron® CINP Adverse Event Profile Most Frequent Adverse Events During Phase 2a CINP Study • Majority of AEs were mild to moderate in severity • Most common AEs were expected and resolved naturally within a few hours after each injection •
Slide 21: Ongoing Halneuron 4-Week Phase 2b CINP Study
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 21 Over 80 Patients Have Been Randomized, 60 Completed Treatment In The Ongoing Halneuron® 4-Week P2b CINP Study Baseline Week 1 Week 2 Week 3 Week 4 Run-in Period Avg. of Days -7 to -1 8 Halneuron® treatment injections spaced over 2 weeks Prima
Slide 22: Intellectual Property & Drug Manufacturing
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 22 Intellectual Property & Drug Manufacturing New Synthetic API for Phase 3 and Commercialization Manufacturing Process and Trade Secrets Method of Use • Target CoM Filing Q4 2025 • Potential Extension to 2045+ New Chemical Entity
Slide 23: SP16 IV CIPN Program Overview
CONFIDENTIAL – Dogwood Therapeutics, Inc. SP16 IV CIPN Program Overview
Slide 24: SP16 Target Background
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 24 SP16 Target Background • Alpha 1 antitrypsin (A1AT) is a member of the serine protease inhibitor family that plays a critical role in protecting the body from the damaging effects of powerful enzyme proteases, including neutrophil elastase •
Slide 25: Preclinical Research Demonstrates SP16 Analgesic Effects
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 25 Preclinical Research Demonstrates SP16 Analgesic Effects Von Frey Mechanical Hypersensitivity Thermal Allodynia SP16 Reduced Both Mechanical and Cold Sensitivity in a Murine Model of Paclitaxel Induced Neuropathy
Slide 26: SP16 Inhibits Pain Responses and Inflammation in Peripheral Nerve Injury Model
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 26 SP16 Inhibits Pain Responses and Inflammation in Peripheral Nerve Injury Model Systemically administered SP16 treatment could block the development of mechanical hypersensitivity • Tactile allodynia develops after peripheral nerve ligation an
Slide 27: SP16 LRP1 Agonism Exhibits Potential to Prevent and/or Repair Nerve Damage
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 27 SP16 LRP1 Agonism Exhibits Potential to Prevent and/or Repair Nerve Damage Associated Chemotherapy • In collaboration with Dr. Wendy Campana at the University of California San Diego, SP16 was tested for its regenerative effects on neurons •
Slide 28: In-vitro Assays Show SP16 Does Not Appear to Interfere with Common Chemotherapy
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 28 In-vitro Assays in Several Cancer Types Shows SP16 Does Not Appear to Interfere with Common Chemotherapy Regimes In-vitro assays in breast and colon cancer shows SP16 does not appear to interfere with the effectiveness of either platinum or t
Slide 29: NCI Funded SP16 Research Plan to be Finalized with FDA
CONFIDENTIAL – Dogwood Therapeutics, Inc. 29 NCI Funded SP16 Research Plan to be Finalized with FDA and Executed at University of VA Baseline Chemotherapy SP16 Starting Dose n=6 SP16 Low Dose n=6 SP16 Mid Dose n=6 SP16 High Dose n=6 Placebo n=8 SP16 IV Phase 1b SP16 IV Phase 2a Eligible for NCI Fund
Slide 30: Corporate Summary
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 30 Corporate Summary • Halneuron® (TTX) = Nav1.7 channel blocker, analgesic → potentially best for treating established CINP pain ⎼ Halneuron® is in Phase 2b development for CINP ⎼ Opportunity to expand ⎼ Nav1.7 channel blocker should have utili
Slide 31: DWTX Projected Research Program Milestones and Catalysts
NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 31 DWTX Projected Research Program Milestones and Catalysts Candidate/Target Target Indication Next Key Milestone Halneuron® Nav 1.7 FDA Fast Track Designation for Treatment of CINP Q4: Dr. Gendreau to Present Halneuron Program Overview at 19th
Slide 32: Investor Relations
CONFIDENTIAL – Dogwood Therapeutics, Inc. Investor Relations Email: IR@dwtx.com NASDAQ: DWTX
Dogwood Therapeutics — Corporate Update (October 2025) on 6ix